Get the Stockscreener App
16.83
36.28%
4.48
After Hours:
17.23
0.40
+2.38%
Tango Therapeutics Inc stock is traded at $16.83, with a volume of 17.98M.
It is up +36.28% in the last 24 hours and up +40.84% over the past month.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
See More
Previous Close:
$12.35
Open:
$12.2
24h Volume:
17.98M
Relative Volume:
5.95
Market Cap:
$2.27B
Revenue:
$66.50M
Net Income/Loss:
$-100.52M
P/E Ratio:
-18.36
EPS:
-0.9165
Net Cash Flow:
$-146.77M
1W Performance:
+47.63%
1M Performance:
+40.84%
6M Performance:
+142.51%
1Y Performance:
+705.26%
1-Day Range:
$11.80
$16.97
1-Week Range:
$10.80
$16.97
52-Week Range:
$1.03
$16.97
Tango Therapeutics Inc Stock (TNGX) Company Profile
Name
Tango Therapeutics Inc
Sector
Industry
Phone
(857) 320-4900
Address
201 BROOKLINE AVENUE, BOSTON
Compare TNGX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
16.83 | 1.66B | 66.50M | -100.52M | -146.77M | -0.9165 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-17-24 | Initiated | Jefferies | Buy |
| Apr-04-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-12-24 | Initiated | Piper Sandler | Overweight |
| Dec-08-23 | Initiated | B. Riley Securities | Buy |
| Oct-20-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-20-21 | Initiated | SVB Leerink | Outperform |
View All
Tango Therapeutics Inc Stock (TNGX) Latest News
Best Biotech Stocks To Add to Your WatchlistMarch 5th - MarketBeat
Assessing Tango Therapeutics (TNGX) Valuation After Earnings Update And New Erasca Trial Collaboration - simplywall.st
Tango rises after Q4 results, clinical pact with Erasca - Seeking Alpha
Tango Therapeutics Shares Rise After Q4 Loss Narrows - marketscreener.com
Tango Therapeutics stock hits 52-week high at $13.66 - Investing.com
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Stifel reiterates Tango Therapeutics stock Buy rating at $15 - Investing.com
Tango Therapeutics stock hits 52-week high at $13.66 By Investing.com - Investing.com India
Tango Therapeutics Reports Net Loss for 2025 and Updates on Clinical Pipeline Progress - geneonline.com
Erasca, Tango Therapeutics Partner on Phase 1/2 Trial for Combination Cancer Therapy - marketscreener.com
Earnings Flash (TNGX) Tango Therapeutics Posts Q4 Loss $0.29 a Share - marketscreener.com
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat - The Manila Times
Tango Therapeutics 2025 10-K: $62.4M Revenue, $(101.6)M Net Loss - TradingView
Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights - The Manila Times
Tango Therapeutics Q4 net loss widens - TradingView
TNGX: Vopimetostat trials progress, cash runway extends to 2028, and leadership transitions completed - TradingView
Tango Therapeutics Q4 Earnings Summary & Key Takeaways - Benzinga
Erasca, Tango test dual-drug attack on tough pancreatic, lung cancers - Stock Titan
Pancreatic cancer bet: Tango sets 2026 pivotal trial with $343M war chest - Stock Titan
Earnings To Watch: Tango Therapeutics Inc (TNGX) Reports Q4 2025 Result - GuruFocus
Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing - The Motley Fool
Biopharmaceutical company Erasca, Inc. (NASDAQ: ERAS) and Tango Therapeutics Inc. (NASDAQ: TNGX) announced a clinical collaboration to jointly conduct clinical evaluation of the combination therapy of ERAS-0015 and vopimetostat. - Bitget
TD Cowen Health Care Conference - marketscreener.com
Examining the Future: Tango Therapeutics's Earnings Outlook - Benzinga
TNGX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
TNGX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Tango Therapeutics Stock Hits Day Low of $10.90 Amid Price Pressure - Markets Mojo
Barclays Global Healthcare Conference - marketscreener.com
Leerink Partners Global Healthcare Conference - marketscreener.com
Insider Sell Alert: Adam Crystal Sells Shares of Tango Therapeutics Inc (TNGX) - GuruFocus
Adam Crystal Sells 54,345 Shares of Tango Therapeutics (NASDAQ:TNGX) Stock - MarketBeat
Tango Therapeutics Officer Sells Shares - TradingView
Tango Therapeutics (TNGX) R&D president sells 54,345 company shares - Stock Titan
Investment Review: Can Tango Therapeutics Inc be recession proofMarket Volume Summary & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Stifel reiterates Tango Therapeutics stock rating at Buy By Investing.com - Investing.com South Africa
Stifel reiterates Tango Therapeutics stock rating at Buy - Investing.com Australia
Tango Therapeutics (NASDAQ:TNGX) Trading Down 10.4%Here's What Happened - MarketBeat
Adam Crystal sells 18,452 shares; Form 144 lists 54,345 RSUs (TNGX) - Stock Titan
Tango Therapeutics (TNGX) Price Target Increased by 11.32% to 15.19 - Nasdaq
Tango Therapeutics Hits New 52-Week High of $13.60, Up 77.79% - Markets Mojo
Tango Therapeutics Achieves 423.87% Return, Emerges as a Multibagger Stock in Biotechnology Sector - Markets Mojo
Investment Report: Is Tango Therapeutics Inc in a long term uptrendJuly 2025 Drop Watch & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Tango Therapeutics (NASDAQ:TNGX) Hits New 1-Year HighHere's Why - MarketBeat
Tango Therapeutics (NASDAQ:TNGX) Now Covered by Mizuho - Defense World
Tango Therapeutics (NASDAQ:TNGX) Trading Up 8.8%Should You Buy? - MarketBeat
Mizuho Initiates Coverage of Tango Therapeutics (TNGX) with Outperform Recommendation - Nasdaq
Tango Therapeutics stock hits 52-week high at 13.5 USD - Investing.com
Tango Therapeutics stock hits 52-week high at 13.5 USD By Investing.com - Investing.com UK
Tango Therapeutics (NASDAQ:TNGX) Coverage Initiated at Mizuho - MarketBeat
Mizuho Initiates Tango Therapeutics at Outperform With $19 Price Target - marketscreener.com
Mizuho initiates Tango Therapeutics stock with outperform rating By Investing.com - Investing.com Canada
Tango Therapeutics Inc Stock (TNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):